ARVN
PFE
RIGL
Bad quarter, better vibes
Arvinas turned in a messy first quarter: losses came in wider than expected and sales landed below estimates. Normally, that’s the kind of report that sends investors straight to the exit. But this one came with a twist — the stock actually rose, and analysts used the aftermath to get a little more optimistic.
The Street said, “Hold up”
BTIG kept its Buy rating on Arvinas and raised its price target from $16 to $18. Barclays also stayed constructive, keeping an Overweight rating and bumping its target from $18 to $20. Translation: Wall Street didn’t love the quarter, but it’s still willing to bet the company can execute from here.
Why investors care
The bigger story isn’t just the earnings miss. Arvinas also highlighted a licensing agreement involving Rigel Pharmaceuticals and Pfizer around its oral PROTAC drug, VEPPANU (vepdegestrant). That gives the company another angle for growth, and it helps explain why traders weren’t in full panic mode after a disappointing print.
Big picture
When a biotech misses on numbers but still gets analyst target hikes, it usually means the market is looking past the quarter and into the pipeline. For Arvinas, that’s the whole game: prove the science, land the milestones, and keep the Street interested long enough for the story to work.